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Abstract
Background: In spite of the disproportionate prevalence of hepatitis C virus (HCV) infection
among drug users, many remain uninformed or misinformed about the virus. Drug treatment
programs are important sites of opportunity for providing HCV education to their patients, and
many programs do, in fact, offer this education in a variety of formats. Little is known, however,
about the level of HCV knowledge among drug treatment program patients, and the extent to
which they utilize their programs' HCV education services.
Methods: Using data collected from patients (N = 280) in 14 U.S. drug treatment programs, we
compared patients who reported that they never injected drugs (NIDUs) with past or current drug
injectors (IDUs) concerning their knowledge about HCV, whether they used HCV education
opportunities at their programs, and the facilitators and barriers to doing so. All of the programs
were participating in a research project that was developing, implementing, and evaluating a staff
training to provide HCV support to patients.
Results: Although IDUs scored higher on an HCV knowledge assessment than NIDUs, there were
many gaps in HCV knowledge among both groups of patients. To address these knowledge gaps,
all of the programs offered at least one form of HCV education: all offered 1:1 sessions with staff,
12 of the programs offered HCV education in a group format, and 11 of the programs offered this
education through pamphlets/books. Only 60% of all of the participating patients used any of their
programs' HCV education services, but those who did avail themselves of these HCV education
opportunities generally assessed them positively. In all, many patients were unaware that HCV
education was offered at their programs through individual sessions with staff, group meetings, and
books/pamphlets, (42%, 49%, and 46% of the patients, respectively), and 22% were unaware that
any HCV education opportunities existed.
Conclusion: Efforts especially need to focus on ensuring that all drug treatment program patients
are made aware of and encouraged to use HCV education services at their programs.
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Background
Over four million current United States residents have
had acute hepatitis C virus (HCV) infection, the most
common blood borne infectious disease in the U.S. [1]. In
view of the ease with which HCV is transmitted by percu-
taneous blood contact [2], current and former drug users
account for a disproportionate number of those with HCV
antibodies as a result of acute infection [1,3]. Of great con-
cern, the majority of individuals with HCV antibodies will
develop chronic HCV infection [4], resulting in serious
liver disease for about 20% of the chronically infected [5].
In spite of its high prevalence among injection drug users
(IDUs), many individuals who inject(ed) drugs do not
know their HCV serostatus [6-9]. This often reflects the
fact that HCV related symptoms may only become appar-
ent when serious viral complications have already devel-
oped, sometimes as much as several decades after
exposure to the virus [10-13]. Thus, many HCV seroposi-
tive individuals remain unaware of their infection until
their health is significantly compromised, treatment
options are severely restricted, and they may have
unknowingly transmitted the virus to others. Importantly,
although the risks of contracting HCV infection are con-
siderably less for non-injection drug users (NIDUs) than
for IDUs, HCV may also be contracted when sharing con-
taminated straws or pipes used for sniffing or smoking
drugs [14,15]. In addition, because drug users who have
not injected drugs in the past may transition to this mode
of drug administration in the future, it is critical that
NIDUs understand the HCV related risks involved in shar-
ing both injection and non-injection drug use equipment.
Regrettably, because drug users' access to and use of med-
ical care is often inadequate, sometimes as a result of the
discrimination they experience from physicians and other
clinicians [16-18], their exposure to accurate HCV infor-
mation is generally limited. In fact, many drug users are
uninformed or misinformed about the mode of transmis-
sion of HCV, the existence of pharmacological therapy for
HCV infection, the risks of disease progression, ways to
prevent this progression (especially abstaining from alco-
hol), and how to avoid contracting the virus if uninfected
[7,8,19]. What information they do have is often faulty or
exaggerated, sometimes downplaying the seriousness of
the infection, or portraying it as a frequently fatal disease
[6-8,20].
Importantly, drug treatment programs are well situated to
fill an important HCV education service gap among drug
users by providing HCV education to their patients. In
fact, our past research indicates that most drug treatment
programs do offer HCV education in one or more formats
(e.g., group sessions, individual sessions, videos, books/
pamphlets) [21,22]. However, this education is some-
times inadequate in a variety of ways, including the lim-
ited number of patients to whom it is offered, the
infrequency with which it is provided, and the lack of
comprehensiveness of the topics covered [21-24]. One
promising way to address these inadequacies is to better
support and enable many direct care staff to provide HCV
education to patients. Most drug treatment program staff
understand the unique needs of the population they
serve, suggesting that they are well positioned to effec-
tively and sensitively communicate accurate and essential
information about HCV and its consequences. Many of
these staff, however, have limited knowledge about the
virus, and some staff lack the skills to effectively commu-
nicate with patients concerning health issues, such as HCV
infection. Thus, supported by a grant from the National
Institute on Drug Abuse of the U.S. National Institutes of
Health, we developed and are implementing a compre-
hensive, 6-hour, skills-based staff training (the "STOP
Hep C staff training") to address many staff's HCV educa-
tion and communication needs [24,25]. Details about the
training, itself, are available elsewhere [26].
The STOP Hep C staff training is intended for staff in both
methadone maintenance treatment programs (MMTPs)
and residential drug-free programs. These treatment
modalities serve many patients at high risk for HCV infec-
tion as a result of past or current drug injection (or are at
serious risk for future transitioning to injection drug use)
and/or the sharing of HCV contaminated non-injection
drug use equipment. In addition, our HCV survey research
from 2001 to 2003 with approximately 600 MMTPs and
drug-free treatment programs throughout the U.S. illumi-
nated differences in the provision of HCV services between
modalities. In particular, MMTPs were more likely to offer
HCV education services to more patients and more com-
prehensively than drug-free programs [22,23,27]. There
were also differences within these modalities with regard
to both aggregate patient characteristics and the HCV serv-
ices offered according to region within the U.S. For exam-
ple, a smaller proportion of drug-free midwestern
programs participating in our past HCV survey research
had a majority of IDU patients (6% of midwestern pro-
grams vs. 17%, 19%, and 24% of southern, northeastern,
and western programs, respectively). Among participating
MMTPs, a smaller proportion of programs in the south
educated all patients about HCV (63% of southern pro-
grams vs. 77%, 76%, and 72% of western, northeastern,
and midwestern programs, respectively), while a greater
proportion of midwestern MMTPs did not educate any
patients about the virus (14% of midwestern programs vs.
2% of southern programs and no northeastern or western
programs). Thus, because of these differences between
and within modalities, and because the training's impact
might vary as a result of these differences, the STOP HepBMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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C staff training research sample includes both MMTPs and
drug-free treatment programs throughout the U.S.
Among the data that are needed to evaluate the impact of
the STOP Hep C staff training on patients receiving sub-
stance abuse treatment in the participating programs are
those that assess (a) their pre-staff training knowledge
about HCV, and (b) their use of their programs' HCV edu-
cation services that were already in place before the staff
training took place. This will enable a comparison of post-
staff training changes, if any, in patients' HCV knowledge
and HCV education services use. Understanding patients'
HCV knowledge and service utilization patterns has
importance beyond an assessment of the impact of the
STOP Hep C staff training. Such an understanding is also
needed in order to inform the substance abuse treatment
field of the extent to which available HCV education serv-
ices are utilized (or under-utilized) in drug treatment pro-
grams, so that appropriate steps can be taken to better
ensure that this vulnerable population is educated about
HCV infection. We therefore performed an analysis of
data collected from a sample of patients (N = 280) receiv-
ing substance abuse treatment in 14 drug treatment pro-
grams throughout the U.S. that were participating in the
STOP Hep C staff training project. Using these data, col-
lected before the STOP Hep C staff training took place, we
report the results of a comprehensive examination of (a)
patients' HCV knowledge, (b) their awareness and actual
use of their programs' existing HCV education services,
and (c) the facilitators and barriers to this service use.
Given the especially heightened risk for contracting and
transmitting HCV among current and former IDUs as
compared with NIDUs, IDUs may have had more past
exposure to HCV information and have had greater inter-
est in continuing to learn about the virus. Thus, there may
be differences between IDUs and NIDUs in their knowl-
edge about HCV and in their awareness and actual use of
HCV education services. We therefore performed our
analyses by comparing data collected from NIDUs (N =
121) and IDUs (N = 159) in the 14 participating pro-
grams.
Methods
Programs Participating in the STOP Hep C Staff Training 
Research
Patients taking part in the current research were recruited
from seven methadone maintenance treatment programs
(MMTPs) and seven residential drug-free treatment pro-
grams that were participating in the STOP Hep C staff
training project during 2005 and 2006. To be eligible to
participate in the project and receive the STOP Hep C staff
training, programs needed to provide drug abuse treat-
ment services on-site and to at least 50 percent of their
patients, and services could not only be for detoxification
or for other short-term treatment (i.e., less than seven
days). So that the training could best serve staff in pro-
grams whose patients were at considerable risk for con-
tracting and transmitting HCV, participating programs
also needed to serve patient populations in which at least
20% were drug injectors, crack smokers, and/or intranasal
cocaine users. By the end of the project's data collection in
2007, programs will have been selected to include an
equal number of MMTPs and drug-free treatment pro-
grams in each of the four U.S. census regions (northeast,
south, midwest, west). Priority in selecting participating
programs was (and continues to be) given to those pro-
grams that took part in our past HCV survey research from
2001 to 2003, which documented the HCV services pro-
vided by drug treatment programs throughout the U.S. In
several instances, we included programs in the STOP Hep
C staff training research that met our inclusion criteria and
were recommended to us either by HCV coordinators in
individual states or by other individuals involved in sup-
porting the implementation of HCV services in drug treat-
ment programs.
The 14 programs that participated in the STOP Hep C staff
training research from September, 2005 through Decem-
ber, 2006 included seven residential drug-free programs:
two in New York City, two in south Florida, two in north
Oregon, and one in Ohio. There were also seven partici-
pating MMTPs: two in New York City, two in Ohio, one in
southern California, one in southern Washington State,
and one in Maryland. Data collected in a telephone inter-
view with each program director before the STOP Hep C
staff training took place documented the HCV services
already in existence and available to patients at the pro-
gram, including those that addressed patients' needs for
HCV education. These 14 programs all offered education
about HCV in one or more forms: e.g., all offered individ-
ual sessions, generally with counselors or nurses; 12
offered group sessions to provide HCV information, often
as part of a health education effort conducted at the pro-
gram by medical staff, counselors, or the local Health
Department; 11 offered HCV education through pam-
phlets or other literature; and one through videos. The
STOP Hep C staff training was intended to update staff's
HCV knowledge and their ability to communicate this
information to patients so that the HCV education serv-
ices that were offered could support patients optimally. As
indicated by the program directors, all of the programs
offered testing for HCV antibodies (three of them on-site
at the treatment program and the rest through referral), 12
offered referral for off-site treatment for HCV infection,
and two offered the treatment on-site at the program.
Participating Patients and Data Collection Procedures
At each site, the director was asked to provide a list of 20
patients who had expressed interest in taking part in the
study, all of whom had an expected length of stay of atBMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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least 3 months. The length of stay requirement was insti-
tuted in order to enable a subsequent assessment of the
potential impact of the STOP Hep C staff training on
patients. To the extent possible, we also requested that this
list of patients from each program contain an approxi-
mately equal number of HCV positive and HCV negative
patients. In the residential drug-free treatment programs,
the list of potential study participants typically consisted
of those patients that volunteered for the study after coun-
selors in the programs' addiction treatment groups
described the research study opportunity to them. While
all patients having an anticipated length of stay of 3
months or more were urged to volunteer, HCV seroposi-
tive patients were especially encouraged to do so in view
of the fact that many patients in the drug-free programs
were HCV seronegative (or HCV sero-unaware). In the
MMTPs, most patients had an anticipated length of stay of
3 months or more and therefore satisfied our eligibility
criterion. In these programs, counselors and/or nurses
generally made patients aware of the research study, and
HCV seronegative patients were especially encouraged to
take part (as the majority of patients in the MMTPs was
HCV infected).
Once compiled at the program, the list of names of poten-
tial study volunteers was provided to the study team by
the program director. These patients were then scheduled
to meet individually on-site at the drug treatment pro-
gram with one of the well-trained research assistants from
our New York based staff. This meeting enabled a more
comprehensive discussion of the patients' possible partic-
ipation, including the fact that patients would be compen-
sated $15 or its equivalent in a gift card for their time. All
potential study participants were given assurances regard-
ing the voluntary nature of the research and the confiden-
tiality of responses including the use of code numbers,
rather than names, to identify study participants. Once the
study was described and all questions were answered,
those patients that agreed to take part in the research
signed an informed consent. In fact, none of the potential
participants declined to agree to participate in the inter-
view after discussing the project with one of our project
staff. In the end, 20 patients in 10 of the 14 programs took
part in the research. In each of two additional programs,
one of the 20 patients on the list of potential study partic-
ipants was unable to take part in the research (yielding a
sample of 19 from those programs). In each of the two
remaining programs, 21 patients appeared on the list of
potential participants supplied by the program director,
and all of these patients were invited to take part in the
research (yielding two program samples of 21 partici-
pants). Thus, between 19 and 21 patients at each program
actually took part in the research. Data used in the analy-
ses conducted for this paper involve those collected from
patients before the staff training took place. Participating
programs understood that the goal of the research was to
examine the impact of an HCV staff training on patients,
staff and the organization. Thus, in view of this stated
goal, it is unlikely that staff would have deliberately edu-
cated participating patients about HCV or urged them to
use HCV services between the time these patients volun-
teered for, and actually took part in the research.
Patients' participation involved the completion of a 30-
minute Audio Computer Assisted Self Interview (ACASI)
instrument. Using headphones, they listened as the survey
questions that appeared on a computer monitor were read
to them, and patients responded to these questions using
a touch screen monitor. Before responding to the survey,
one of the project's research assistants worked with the
patients individually using a variety of practice questions,
and helped them become familiar with the use of the
ACASI and the instrument itself. Once the patient was
comfortable with the ACASI procedure, the research
assistant remained nearby to answer any questions or deal
with any problems in completing the instrument. Care
was taken to avoid observing patients' responses to the
survey questions. The study protocol and study instru-
ments were approved by the Institutional Review Board of
the National Development and Research Institutes, Inc.
Data Collected from Patients
Patients were asked to respond to questions involving
their socio-demographics (e.g., sex, age, race, ethnicity,
marital status, education level), drug use and drug treat-
ment program history, current health (including HIV and
HCV status), and health insurance coverage. They were
also asked to respond to questions concerning their needs
in terms of HCV education, testing, and medical care and
support services, the availability of HCV services in these
areas at the drug treatment program that they were cur-
rently attending, and their use of these services. In addi-
tion, they were asked to indicate, on a scale from 1 (do not
agree at all) to 10 (completely agree), the extent to which
they agreed with statements concerning some reasons
why the use of these services may have been facilitated or
made more difficult.
Patients were also asked to respond to a 20 item HCV
Knowledge Assessment. As we describe in more detail
elsewhere [28], the research team created this assessment
to specifically address HCV-related information that is
especially relevant for drug treatment programs and their
patients. For each item, respondents indicated if the item
was true or false or if they did not know. The 20 items
include those concerning HCV transmission risk and risk
behaviors; HCV diagnosis and disease progression; cur-
rent HCV treatment options (including for drug depend-
ency patients in MMTPs and other treatment programs);
treatment outcomes and health maintenance if HCVBMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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infected; differences between the various types of hepatitis
and the availability of vaccines for them; and HIV and
HCV co-infection. A total score was obtained for each
respondent on the HCV Knowledge Assessment by deter-
mining the number of items that was correctly endorsed.
Each individual's score could therefore range between 0
and 20.
Statistical Analysis
Analyses that compare the 121 NIDUs with the 159 IDUs
in the 14 participating programs use chi-square tests (for
categorical variables) and t-tests (for continuous varia-
bles) to test for statistical significance. P-values for results
significant at the p = .05 level or less are reported.
Results
Characteristics of the Participating Patients
As can be seen in Table 1, close to half (45.7%) of the par-
ticipating patients were female. Relative to the NIDUs, the
IDUs included a significantly smaller proportion of His-
panic patients (12.6% vs. 25.6%; p = .005), and a signifi-
cantly smaller proportion of non-White patients (18.9%
vs. 44.6%; respectively, were Black, and 15.1% vs. 19.0%,
respectively, were of races other than Black or White; p <
.001). Overall, participating NIDUs were significantly
younger than participating IDUs (37.7 years vs. 41.2
years; p = .005), and were less likely to be married or in a
common law relationship (12.4% vs. 27.0%; p = .003).
About two thirds of the sample (69.3%) had at least a
high school degree or its equivalent.
In terms of the specific drugs used in the 6 months before
treatment, three out of five (59.5%) of the participating
patients used cocaine or crack, and about half (47.1%)
used alcohol during these 6 months. IDUs were signifi-
cantly more likely than NIDUs to use opiates (80.9% vs.
36.8; p < .001) during this time. In fact, most (70.1%)
IDUs identified opiates as their primary drug in the 6
Table 1: Characteristics of Participating Patients: Non-Injectors and Injectors
Non-Injectors
(N = 121)
Injectors
(N = 159)
All Patients
(N = 280)
Female (%) 43.8 47.2 45.7
Hispanic (%)** 25.6 12.6 18.2
Race (%)***
Black 44.6 18.9 30.0
White 36.4 66.0 53.2
Other 19.0 15.1 16.8
Age (mean, s.d.)** 37.7 (10.3) 41.2 (10.2) 39.7 (10.4)
High School degree or above (%) 66.1 71.7 69.3
Married/Common Law (%)** 12.4 27.0 20.7
Most frequently used drugs in the 
6 months before treatment (%)
Opiates*** 36.8 80.9 62.0
Cocaine or crack 60.7 58.6 59.5
Alcohol 53.0 42.7 47.1
Primary drug used in the 6 months 
before treatment (%) ***
Opiates 33.3 70.1 54.4
Cocaine or crack 35.9 8.3 20.1
Alcohol 16.2 6.4 10.6
Other 14.5 15.3 15.0
Years since first used primary drug 
(mean, s.d.)**
17.5 (10.6) 21.2 (11.2) 19.6 (11.0)
Used primary drug every day in 6 
mos. before treatment (%)***
70.1 86.6 79.6
In drug treatment before this time 
(%)***
52.1 73.6 64.3
- Of these, times in drug tx. in the 
past (mean, s.d.)
3.3 (2.9) 4.3 (9.4) 4.0 (7.7)
Self reported health is poor or fair 
(%)***
23.3 45.3 35.8
Reports having tested HIV+ (%) 7.4 5.0 6.1
Reports having tested HCV+ 
(rather than HCV- or HCV 
unaware) (%)***
6.6 56.6 35.0
Does not have health insurance 
(%)
47.5 36.1 41.0
** p < .01
*** p < .001BMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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months before entering drug treatment, while NIDUs
were most likely to identify cocaine or crack (35.9%), opi-
ates (33.3%), or alcohol (16.2%) [p < .001]. Overall,
IDUs were significantly more likely than NIDUs to use
their primary drug every day in the 6 months before enter-
ing the drug treatment program (86.6% vs. 70.1%; p =
.001), and to have used their primary drug for a longer
period of time (21.2 years vs. 17.5 years, p = .006). With
regard to their drug injection history and practices, IDUs
had been injecting for 17.8 years, on average (s.d. 12.0),
and 88.1% injected drugs in the 6 months before entering
the drug treatment program (data not shown in Table 1).
Of this latter group of participants, two thirds (67.3%)
used others' syringes and/or drug paraphernalia (e.g., cot-
tons, rinse water) during this time, placing themselves
and others at considerable risk for contracting or transmit-
ting HCV and other blood borne infections.
Given their extensive drug use history, it is not surprising
that most IDUs and NIDUs had been in a drug treatment
program in the past, although this was significantly more
likely to have been the case among IDUs than NIDUs
(73.6% vs. 52.1%; p < .001). All participating patients that
had a drug treatment program history had generally been
in such programs about 4 prior times.
Overall, IDUs were significantly more likely than NIDUs
to report their health as being poor or fair (45.3% vs.
23.3%; p < .001). In all, 6.1% of the patients report having
tested positive for HIV, and 35.8% report having tested
HCV positive, although IDUs were significantly more
likely to indicate a positive test for HCV antibodies than
NIDUs (56.6% vs. 6.6%; p < .001). Unfortunately,
although many patients have serious health issues such as
these, about two in five (41.0%) report that they do not
have health insurance.
HCV Knowledge Assessment
The 280 participating patients scored, on average, 11.1
(s.d. = 4.1) correct out of 20 on the HCV Knowledge
Assessment, demonstrating limited knowledge about
HCV. While IDUs scored significantly higher, on average,
than did NIDUs (11.9 [s.d. = 3.8] vs. 10.1 [s.d. = 4.3]; p <
.001), their scores also suggest many gaps in their knowl-
edge about HCV.
Of note, although a significantly greater proportion of
IDUs as compared with NIDUs had been in a drug treat-
ment program before this time (suggesting that a greater
proportion of participating IDUs may have been exposed
to HCV education in the drug treatment program venue),
there was no significant relationship between having a
history of past drug treatment and a higher score on the
HCV Knowledge Assessment (Pearson r = .08; p = .17).
Nor was there a significant correlation for those who had
such a history between their HCV Knowledge Assessment
scores and the number of times they had been in a drug
treatment program in the past (Pearson r = .02; p = .75).
As can be seen in Table 2, when the individual items on
the HCV Knowledge Assessment are examined separately,
there were statistically significant differences between the
NIDUs and the IDUs on 10 of the 20 items. On almost all
of these items, IDUs were significantly more likely than
NIDUs to correctly endorse the items. These items had to
do with HCV transmission; the duration of HCV treat-
ment; distinguishing the various types of hepatitis infec-
tions, methadone and its interaction with HCV treatment;
the absence of an HCV vaccine; the possibility of sponta-
neous clearance of HCV infection; and the risk of contract-
ing HCV relative to HIV.
Self-reported need for HCV education
As can be seen in Table 3, when asked to rate their need
for HCV education, patients assigned a score of 5.7, on
average, on a scale from 1 to 10, with '10' indicating the
greatest need.
Awareness and use of HCV education services
At 12 of the 14 programs (6 residential drug-free programs
and 6 MMTPs), HCV education was offered in a group for-
mat. Among the participating patients in these programs,
only three in five (57.7%) were aware that such a service
was available at their programs. Of these, only 58.3%
received the education in this way. Thus, only 33.6% of
the patients in programs that offered HCV education in a
group format received HCV education in this manner.
At each of the 14 programs, patients could receive HCV
education in individual sessions with staff. In all, 50.4%
of patients were aware that HCV education was available
through individual sessions, but only 60.3% of the partic-
ipating patients who were aware of this availability actu-
ally received HCV education in this way. Thus, only
30.4% of the patients were educated about HCV in indi-
vidual sessions with staff.
Eleven of the programs (6 MMTPs and 5 residential drug-
free programs) offered HCV education through pam-
phlets or books that the program distributed. In all,
53.4% of the patients in these 11 programs were aware
that HCV education was available through books or pam-
phlets (although a significantly greater proportion of
IDUs than NIDUs were aware of the availability of this lit-
erature: 61.6% vs. 44.9%; p = .013). As a group, only
70.9% of those who were aware of the availability of HCV
information through books or pamphlets actually
received HCV education in this way. Thus, only 37.9% of
the patients in programs that offered HCV educationBMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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through books or pamphlets were actually educated about
HCV through this literature.
A small proportion (13.6%) of patients received educa-
tion about HCV through videos or in other ways different
from either group or individual sessions with staff, or
through books and pamphlets. In all, only three in five
patients (59.6%) received HCV education in any form,
and almost a quarter (22.5%) was not even aware that any
type of HCV education was available at their programs.
Facilitators and Barriers to Using Available HCV Services
The 134 patients that received HCV education either
through group sessions or individual sessions with staff,
were asked to rate on a scale from 1 to 10 the extent to
which they agreed with statements that described a
number of possible facilitators for this receipt, with '10'
indicating they completely agreed. These included "The
medical staff I deal with listen to my concerns about hep-
atitis C" (average rating 8.1 [s.d. 2.8], median rating 9.0);
"The counselors I deal with listen to my concerns about
hepatitis C" (average rating 8.0 [s.d. 2.6], median rating
9.0); "The medical staff I deal with know a lot about hep-
atitis C" (average rating 7.6 [s.d. 3.0], median rating 9.0);
"The staff I deal with make sure that I understand the
information they give me about hepatitis C" (average rat-
ing 7.5 [s.d. 3.0], median rating 9.0); "The counselors I
deal with know a lot about hepatitis C" (average rating 7.2
[s.d. 2.9], median rating 8.0); and "The staff I deal with
bring up the topic of hepatitis C with me" (average rating
6.0 [s.d. 3.3], median rating 6.0). There were no statisti-
cally significant differences between NIDUs and IDUs
concerning these facilitators.
We also asked the 92 patients that were aware of the avail-
ability of HCV education services through group and/or
individual sessions with staff, but did not use at least one
of these services, to rate on a scale from 1 to 10 the extent
to which they agreed with statements concerning some
reasons why they may not have done so. These included
"If I ask about hepatitis C or go to a group about it, people
might think I am infected" (average rating 3.9 [s.d. 3.5],
median rating 2.0); "The person or people who provide
the information know too little about hepatitis C" (aver-
age rating 3.3 [s.d. 3.1], median rating 2.0); "The person
or people who provide the information use words I don't
understand" (average rating 2.9 [s.d. 2.9], median rating
1.0); and "I don't want to deal with hepatitis C right now"
(average rating 2.2 [s.d 2.1], median rating 1.0). In addi-
tion, the 58 patients in the 12 programs that offered HCV
education in a group format who were aware of the avail-
ability of this service, but did not use it gave an average
Table 2: Proportion of Correct Responses to Questions about Hepatitis C: Non-Injectors and Injectorsa
Non-Injectors
(N = 121)
Injectors
(N = 159)
All Patients
(N = 280)
1. You can get the hepatitis C virus by using a hepatitis C infected person's razor.* 73.6 84.3 79.6
2. If you have hepatitis C, drinking a few glasses of wine every day won't hurt your liver. 74.4 81.1 78.2
3. Hepatitis C can be spread when injection drug users share their rinse water.*** 61.2 85.5 75.0
4. If a person's liver function tests are normal, the person definitely doesn't have hepatitis C. 66.1 75.5 71.4
5. Hepatitis C infected clients should get vaccinated for hepatitis A and hepatitis B. 68.6 71.7 70.4
6. You'll probably get hepatitis C if you eat food from a plate that wasn't cleaned well.** 57.9 73.6 66.8
7. Most new hepatitis C infections are caused by injection drug use. 65.3 66.7 66.1
8. All hepatitis C infected people will get rid of the virus if they stay on hepatitis C medications for at least one 
year.
59.5 67.3 63.9
9. The only way a doctor can really know how much the hepatitis C virus has hurt a person's liver is by doing a 
liver biopsy.
62.8 63.5 63.2
10. Hepatitis C is mostly spread through risky sex.*** 48.8 74.2 63.2
11. When people share needles, it's easier to get HIV than hepatitis C.** 47.9 65.4 57.9
12. You should never take medications for hepatitis C if you have HIV. 49.6 57.2 53.9
13. Although the risk is low, it is possible to get hepatitis C by sharing pipes when smoking drugs. 54.5 52.8 53.6
14. Drug users must stop taking methadone before starting HCV medication.*** 40.5 62.9 53.2
15. There is a vaccine that protects against hepatitis C.*** 38.8 60.4 51.1
16. Medication to treat hepatitis C can work in active drug users. 45.5 39.0 41.8
17. If you take medications for hepatitis C, you need to take them for many years.** 28.9 44.0 37.5
18. Bleaching needles is a good way for injection drug users to avoid getting HCV.* 38.8 25.8 31.4
19. Most people who have hepatitis C will get serious liver disease. 16.5 19.5 18.2
20. Some people infected with HCV can get rid of it without needing to take any medications.* 7.4 17.6 13.2
aCorrect answers: 1. True; 2. False; 3. True; 4. False; 5. True; 6. False; 7. True; 8. False; 9. True; 10. False; 11. False; 12. False; 13. True; 14. False; 15. 
False; 16. True; 17. False; 18. False; 19. False; 20. True
* p < .05
** p < .01
*** p < .001BMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
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rating of 4.8 (s.d. 3.7 and median of 5.0) to "The group
education about hepatitis C was given at a bad time for
me." Finally, the 34 patients that were aware of the avail-
ability of literature on HCV at the program but did not use
it were asked to rate, on a scale from 1 to 10, why this was
the case. Respondents gave an average rating of 1.7 (s.d.
1.7 and median rating of 1.0) to "The printed information
about hepatitis C is hard to understand" and an average
rating of 1.4 (s.d. 1.6 and median rating of 1.0) to "The
things written about hepatitis C that they give out are not
in my language." There were no statistically significant dif-
ferences between NIDUs and IDUs concerning any of
these barriers.
Discussion
Our results are consistent with the literature that docu-
ments drug users' limited knowledge about HCV infec-
tion, with scores on a 20-item HCV Knowledge
Assessment averaging only a little better than random.
Although participating IDUs averaged only 60% correct
on this assessment, they scored higher than participating
NIDUs overall, and a greater proportion of NIDUs cor-
rectly endorsed 9 of the 20 individual items. This may
reflect IDUs' recognition of their need to be informed
about HCV in view of the high prevalence of the virus
among those who inject(ed) drugs, and their greater per-
sonal stake in pursuing information about HCV. The need
for this information is considerable, however, for all of
those at risk for contracting and transmitting the virus,
including NIDUs. Participating patients in our research
acknowledged this need, at least to some extent, rating it
5.7 on a scale from 1 to 10.
Given the limited knowledge about HCV on the part of
these NIDUs and IDUs and their moderate recognition of
their need for HCV education, it is of considerable con-
cern that less than two thirds of them obtained such edu-
cation in any form at their drug treatment programs. In
particular, while all 14 of the programs offered HCV edu-
cation in individual sessions with staff, 11 through books/
pamphlets, and 12 offered HCV education in group ses-
sions, actual receipt of these specific types of HCV educa-
tion services ranged from only 30.4% for individual
sessions with staff to 37.9% for books or pamphlets. All
patients can benefit from the receipt of these services in
each of these forms.
Clearly, a necessary first step in patients' use of existing
HCV education services at their programs is awareness of
their existence; our data show that a substantial propor-
tion of drug treatment program patients are unaware of
HCV education opportunities. Only 57.7% of the IDUs
and NIDUs were aware of the availability of group ses-
sions that covered HCV information, and only half
(50.4%) was aware of the availability of individual ses-
sions with staff to discuss HCV. This lack of awareness on
the part of so many patients represents missed opportuni-
ties to address both IDUs' and NIDUs' HCV related
knowledge gaps and concerns.
Importantly, of those aware of the HCV education services
offered at their programs, our research did not identify
many substantial barriers to obtaining this education. For
some, the time at which group HCV education sessions
was offered was an obstacle to attending these sessions, as
was the concern that attending such a session or asking
about HCV might cause others to think they had HCV
infection. Overall, however, those who were educated
about HCV at their programs gave high marks to coun-
selors and medical staff in terms of listening to their con-
Table 3: Patients' Needs, Awareness and Receipt of Programs' HCV Education Services: Non-Injectors and Injectors
Non-Injectors
(N = 121)
Injectors
(N = 159)
All Patients
(N = 280)
Needed HCV education when entered treatment (scale from 1 to 10) (mean, s.d.) 5.4 (3.5) 6.0 (3.5) 5.7 (3.5)
Received HCV education in a group formata (%) 38.7 29.6 33.6
- Aware that HCV education is available in group sessions (%) 62.3 54.1 57.7
- Of those aware of its availability, received HCV education in a group format (%) 62.1 54.8 58.3
Received HCV education in 1:1 sessions with staff (%) 26.4 33.3 30.4
- Aware that HCV education is available in 1:1 sessions (%) 47.1 52.8 50.4
- Of those aware of its availability, received HCV education in 1:1 sessions (%) 56.1 63.1 60.3
Received HCV information at the program through pamphlets/bookletsb (%) 34.6 41.1 37.9
- Aware that HCV information is available at the program in pamphlets/books (%)* 44.9 61.6 53.4
- Of those aware of its availability, received HCV information in pamphlets/books (%) 77.1 66.7 70.9
Received HCV education in some other way (e.g., videos) (%) 14.9 12.6 13.6
Received at least one form of HCV education at the program (%) 62.0 57.9 59.6
Unaware of availability of any HCV education resources at the program (%) 22.3 22.6 22.5
aOf the 241 patients in the 6 MMTPs and 6 drug-free treatment programs at which HCV education in a group format was offered
bOf the 219 patients in the 6 MMTPs and 5 drug-free treatment programs at which HCV education through pamphlets/books was offered
* p < .05BMC Health Services Research 2007, 7:39 http://www.biomedcentral.com/1472-6963/7/39
Page 9 of 10
(page number not for citation purposes)
cerns about HCV, knowing a lot about the virus, and
making sure that patients understood the information
that was given. Thus, efforts need to be directed at making
certain that patients are informed about HCV education
opportunities at their programs, and encouraged to make
use of them.
We acknowledge a number of limitations to the research.
First, the patients taking part in our research may not nec-
essarily be representative of IDUs and NIDUs in MMTPs
and residential drug-free treatment program patients
nationwide, or even at their programs. With regard to the
latter limitation, however, given the manner in which
they were recruited, we are unaware of any specific biases
in the types of patients who volunteered for the research
and whose names were provided by the program directors
at the participating programs. In addition, because
patients were made aware of the opportunity to take part
in the research by drug treatment program staff, any
unknown bias that might (in fact) exist would likely be in
the direction of involving more patients whose HCV
knowledge and use of HCV education services was greater
than average at each program. Thus, results from this
study should be viewed as possibly understating the lim-
ited HCV knowledge and use of HCV education services at
these programs. Second, HCV serostatus was categorized
according to participants' self-report. While attempts were
made to solicit volunteers for the research that included
an approximately equal number of HCV seropositive and
HCV seronegative patients in each of the programs, no
participant was excluded from the study on the basis of
her/his self-reported HCV status. Thus, combined with
our emphasis on ensuring patient confidentiality, there is
no specific reason to believe that the self-report is inaccu-
rate. There is also the possibility that participants pro-
vided socially desirable responses to our questions. The
use of ACASI, however, is likely to have encouraged them
to respond truthfully, as their responses were not pro-
vided directly to an interviewer. Finally, with regard to the
facilitators and barriers concerning the use of HCV educa-
tion services, patients' responses reflect the extent to
which they agreed or disagreed with statements that we
provided. Thus, patients may have had other reasons that
we did not ask about concerning why they did or did not
use available HCV education services at their programs.
Conclusion
Current and former drug users have significant health
issues, and many of them lack health insurance coverage
and face discrimination and stigma in the community.
Although drug treatment programs offer an important
venue to support drug users' HCV related needs, our study
participants, drawn from 14 different drug treatment pro-
grams throughout the U.S. and receiving treatment in two
different modalities, had limited knowledge about HCV.
This, coupled with the overall satisfaction expressed by
those who used HCV education services at their drug treat-
ment programs, suggests that many drug treatment pro-
gram patients may be unaware of much needed and
valuable opportunities to learn about HCV-related issues
in their programs. Our research also suggests the need for
drug treatment programs to find ways to make more
patients aware of available HCV education opportunities
and encourage them to use these services. Without the
current availability of a vaccine for HCV infection, and
only limited success with HCV pharmacological treatment
[29,30], it is imperative that drug treatment program
patients obtain critical information to support reducing
their risk for contracting HCV, limiting its spread to oth-
ers, and maintaining their health to the greatest extent
possible.
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